FIELD: biochemistry.
SUBSTANCE: invention relates to a procoagulant bispecific antibody that specifically binds CD47 and PD-L1. A nucleic acid encoding the said antibody; a vector or cell containing the said nucleic acid; a pharmaceutical composition containing the said antibody, are also disclosed. The following is disclosed: a method of obtaining a host cell; a method of producing the said antibody; a method of inhibiting the biological activity of PD-L1 and CD47 using the said antibody; a method of treating a disease or disorder mediated by PD-L1 and CD47 using the said antibody; the use of the said antibody to treat a disease or disorder mediated by PD-L1 and CD47.
EFFECT: invention makes it possible to effectively treat diseases or disorders mediated by PD-L1 and CD47.
45 cl, 7 dwg, 14 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
